SRIJAN TIWARI

Drug & Cosmetics Law Insights — Advocate Srijan Tiwari Blog

Expert analysis of drug law developments, CDSCO notifications, Delhi High Court judgments, and regulatory enforcement trends — written for pharmaceutical corporate legal and compliance teams.

NSQ CasesNSQ Defence

How Delhi Courts Are Approaching NSQ Defences in 2025–26: Key Trends

The past 18 months have seen a significant shift in how Delhi district courts are evaluating NSQ defences. With a spate of new judgments from Delhi High Court emphasising the importance of proper sampling procedure and analyst qualification, pharmaceutical companies have stronger grounds for challenge than ever before. Here is what your legal team needs to know.

February 28, 20268 min read
Read Article
Delhi High CourtHigh Court Judgment

Landmark: Delhi HC Quashes Drug Licence Suspension Without Prior Hearing

In a significant ruling in early 2026, the Delhi High Court quashed a manufacturing licence suspension order issued by the Delhi state drug authority because the company was not given an opportunity to be heard before the suspension. The judgment reaffirms the fundamental importance of natural justice in drug regulatory action. Full case analysis inside.

January 30, 202610 min read
Read Article
Cosmetics LawCompliance Guide

Cosmetics Rules 2020 — What Changed, What Remains Confused, and What Companies Get Wrong

The Cosmetics Rules, 2020 represented a significant overhaul of Indian cosmetics regulation. But four years into implementation, many companies are still making critical compliance errors — particularly around BIS certification, import cosmetics registration, and the boundary between drugs and cosmetics. Here is a plain-language guide to getting it right.

January 15, 202612 min read
Read Article
NSQ CasesLitigation Strategy

Challenging the Government Analyst Report in Delhi NSQ Cases: A Practitioner's Guide

The Form 29 government analyst report is the cornerstone of any NSQ prosecution — and it is also the most fertile ground for a successful defence. In this detailed article, we examine the five most common procedural and methodological deficiencies we encounter in Delhi drug authority analyst reports, and how to build a defence strategy around each one.

December 20, 202514 min read
Read Article
Corporate ComplianceRisk Management

Building a Drug Law Risk Management Programme for Pharmaceutical Corporations in India

For pharmaceutical corporations of scale, drug law risk is not a question of 'if' but 'when'. An NSQ notice, a state drug authority inspection finding, or a CDSCO quality alert can materialise at any time. The companies that navigate these situations with minimal business impact are those that have built proactive legal risk management into their operations. Here is how to do it.

December 5, 202511 min read
Read Article

Categories

  • NSQ Cases12
  • CDSCO Updates8
  • Delhi High Court15
  • Cosmetics Law6
  • Regulatory Reform9
  • Corporate Compliance7

About the Author

ST

Advocate Srijan Tiwari

Drug & Cosmetics Law Specialist

Delhi High Court · Since 2010

All articles on this blog are written or reviewed by Advocate Srijan Tiwari based on 14+ years of exclusive drug law litigation practice at Delhi High Court. Content is for informational purposes and does not constitute legal advice.

Drug Law Newsletter

Monthly updates on CDSCO notifications, Delhi High Court drug law judgments, and enforcement trends. For pharmaceutical corporate legal and compliance teams.

No spam. Unsubscribe anytime.

Got a Drug Law Question?

Articles give general guidance — for specific legal advice on your company's situation, speak with Advocate Srijan Tiwari directly.

Ask on WhatsApp

Stay Ahead of Drug Law Developments in Delhi

Subscribe to our monthly newsletter or WhatsApp us to discuss how current regulatory developments may affect your company.